Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tuberculosis and Kidney Transplantation

Autor: H. Riska, Börje Kuhlbäck

Publikováno v: Acta Medica Scandinavica. 205:637-640

Immunosuppressive treatment enhances the risk of pulmonary and other infections. Tuberculosis is a predictable complication in transplanted patients. The present material comprises 584 kidney transplantation patients, ten of whom had had a previous h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b0c381cbc0cfba8c572f50cf105dae1
https://doi.org/10.1111/j.0954-6820.1979.tb06118.x

Zobrazit plný text záznamu

Treatment of Malignant Pleural Mesothelioma with Carboplatin, Liposomized Doxorubicin, and Gemcitabine: A Phase II Study

Autor: Anders Vikstrom, Gunnar Hillerdal, H. Riska, Anders Hjerpe, Jens Benn Sørensen, Stein Sundstrøm

Publikováno v: Journal of Thoracic Oncology. 3(11):1325-1331

BackgroundMalignant pleural mesothelioma has a poor prognosis and there is limited effect of treatment. The Nordic Mesothelioma groups decided in the year 2000 to investigate a combination of liposomized doxorubicin, carboplatin, and gemcitabine for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3182a7b8f089b050015b79d3658afda7

Zobrazit plný text záznamu

Studies of cytokine levels in bronchoalveolar fluid lavage from patients with interstitial lung diseases

Autor: H. WOLFF, A.‐M. TEPPO, P. MUTANEN, S. SUTINEN, R. BACKMAN, A. PIETINALHO, H. RISKA

Publikováno v: Scandinavian Journal of Clinical and Laboratory Investigation. 63:27-36

Cytokine levels in bronchoalveolar lavage fluid from patients with eosinophilic pneumonia (n = 7), allergic alveolitis (n = 11), (cryptogenic) fibrosing alveolitis (n = 8), sarcoidosis (n = 10) were determined, as well as levels in control samples fr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e98ec718e530da8e87a117f83d38592
https://doi.org/10.1080/00365510310000466

Zobrazit plný text záznamu

Alveolar lavage fluid (ALF) of normal volunteer subjects: cytologic, immunocytochemical, and biochemical reference values

Autor: S. Sutinen, H. Riska, S.H. Sutinen, R. Backman, B. Fröseth

Publikováno v: Respiratory Medicine. 89:85-92

Objective: Pooled bronchoalveolar lavage fluid (BALF), the return of lavage, contains both bronchial and alveolar material which differ from each other. Artifacts may be created by filtering, centrifuging and washing cells before cytopreparation. Thi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d76f82a7f51d6b6203cdf4dfbbc3c7de
https://doi.org/10.1016/0954-6111(95)90189-2

Zobrazit plný text záznamu

Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer

Autor: Petr Zatloukal, R. P. Abratt, J. Rolski, H. Riska, C.P. Schneider, U. Gatzemeier, Ying-Huang Tsai, Eng Huat Tan, G. Carteni, E. Aitini, T. Grodzki

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 20(7)

Background: The study compared the efficacy of a first-line treatment with day 1 i.v. vinorelbine (NVBiv) and day 8 oral vinorelbine (NVBo) versus docetaxel (DCT) in a cisplatin-based combination in advanced non-small-cell lung cancer, in terms of ti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49b20f30245306ac1990983e85a9f613
https://pubmed.ncbi.nlm.nih.gov/19633043

Zobrazit plný text záznamu

Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer

Autor: Jean-Luc Canon, Patrick Peterson, Michael Lahn, Robert Pirker, H. Riska, Pekka Mali, Johan Vansteenkiste, William J. John

Publikováno v: Investigational new drugs. 23(3)

Aprinocarsen is a specific antisense oligonucleotide inhibitor of protein kinase C-alpha. This study aimed to evaluate the response rate to combination therapy with aprinocarsen, gemcitabine and cisplatin, in chemonaive patients with advanced/metasta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25efaf308c362f1783ebaacd72aeebfa
https://pubmed.ncbi.nlm.nih.gov/15868384

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání